EpiPen maker Mylan is racing to put down a revolt from shareholders outraged by a $98 million pay package for its former CEO. ISS chastised the Mylan board for "multiple egregious pay decisions" and a failure to heed "warning signs" ahead of last summer's scandal over EpiPen pricing. Both firms urged Mylan shareholders to vote against the nonbinding "say-on-pay" proposal at the company's June 22 annual meeting. Mylan's pay practices were unpopular even before the EpiPen scandal. The EpiPen controversy "has laid bare a record of poor stewardship and responsiveness" by Mylan's board," ISS said.

Source: CNN June 13, 2017 15:11 UTC